Skip to content
Politically.com Search all
Menu

2026 · 3rd Quarter (July 1 - Sep 30)

NOVO NORDISK INC.

Filed by NOVO NORDISK INC..

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-11-04 06:26:19 UTC.

Source-reported fields

Filing overview

Type
3rd Quarter - Report
Posted
Oct 20, 2026
Income
Not reported
Expenses
$2,010,000.00
Filing UUID
88523cb7-0b29-4b43-9204-f724aa681a62
Termination date
Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Obesity, Treat and Reduce Obesity Act, IRA implementation, General engagement around drug pricing.

CPT · Copyright/Patent/Trademark

S. 150, Affordable Prescriptions for Patients Act, Patent Protection, General IP Issues, Safe Drugs Act and Pharmaceutical Compounding.

Literal federal measure citations: S. 150

TAX · Taxation/Internal Revenue Code

International and corporate tax issues.

TAR · Tariff (miscellaneous tariff bills)

Tariffs and trade policy.

HCR · Health Issues

Obesity, Treat and Reduce Obesity Act, Insulin Pricing/affordability, IRA implementation and drug pricing legislation, supply chain, 340B, Intellectual Property/patent protection, S. 150 - the Affordable Prescriptions for Patients Act, Protect 340B Act, PBM Reform Act, Safe Drugs Act and Pharmaceutical Compounding.

Literal federal measure citations: S. 150

BUD · Budget/Appropriations

Labor-HHS Appropriations Bill, Military Construction, Treat and Reduce Obesity Act, Safe Drugs Act and Pharmaceutical Compounding, FDA Agricultural Appropriations bill.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.